# TwinCure.AI  
**"Smarter Trials, Safer Treatments."**  

Presented by **GlitchBorne Team**  

---

## ğŸš¨ Problem  

Cancer remains one of the most pressing health crises in Tunisia and beyond:  

- **60 new infections every day** in Tunisia.  
- In **2023 alone, 22,000+ new cases** were reported, with patients facing delayed treatments, limited resources, and financial burdens.  
- Example: *Maryam, a 38-year-old mother of four from Kasserine, endured long waits and exhausting treatment journeys in addition to her illness.*  
- On the pharmaceutical side:  
  - It takes **$2.6B and 10â€“15 years** to bring a single drug to market.  
  - **90% of drugs fail in clinical trials**.  
  - Current â€œone-size-fits-allâ€ testing ignores unique genetic and lifestyle differences.  
  - Patient data is often **fragmented, insecure, and untrusted**.  

---

## ğŸ’¡ Solution â€” A New Era in Drug Testing  

**TwinCure.AI** introduces **AI-powered Digital Twins secured by Blockchain**:  

- A **digital replica of each patient** integrating genetic, physiological, and lifestyle data.  
- **Simulate drug responses** virtually before real-world trials.  
- **Blockchain integration** ensures secure, transparent, and trustworthy data management.  

### ğŸ§¬ Workflow: From DNA to Digital Twin  
1. Sequence Input & Validation  
2. Genomic & Molecular Analysis  
3. Drug Design Engine  
4. Clinical Prediction  
5. Visualization & Interaction  

### âš™ï¸ Technical Highlights  
- **Machine Learning Models**: e.g., Random Forest to predict clinical markers from DNA sequences.  
- **Mathematical Optimization**: AI-driven drug design acceleration.  
- **Blockchain Infrastructure**: Immutable storage, tokenized data sharing, and secure marketplaces.  

---

## ğŸŒ Impact  

- **Global & Local Reach**: Supports developing nations like Tunisia and other African countries in overcoming healthcare barriers.  
- **Safer, Faster Trials**: â€œTest drugs on your digital twin before they ever touch your body.â€  
- **Precision Medicine**: Ethical, personalized, and secure drug testing.  

---

## ğŸ“Š Market Opportunity  

- **TAM** (Total Addressable Market): ~$1.55 trillion  
- **SAM**: ~20 million patients  
- **SOM**: ~700,000 patients  
- Positioned at the intersection of **Personalized Medicine** and **Blockchain for Healthcare**.  

---

## ğŸ† Competitive Landscape  

| Company           | Focus                         | TwinCure.AI Differentiator              |
|-------------------|-------------------------------|------------------------------------------|
| InstaDeep         | General AI/biotech            | Blockchain-secured digital twins          |
| Isomorphic Labs   | AI drug discovery             | Oncology specialization                  |
| Insilico Medicine | AI-driven pharma              | Tokenized simulation data                |
| Owkin             | Collaborative ML for health   | Full DNA-to-drug pipeline with blockchain |

---

## ğŸ’° Business Model  

- **B2B AI-as-a-Service (AIaaS)** targeting pharmaceutical companies, biotech firms, research labs, and health regulators.  

**Pricing**  
- Starter for labs: **$299/month**  
- Enterprise: Custom contracts  

**Revenue Streams**  
- SaaS licensing  
- Project-based contracts  
- Tokenized simulation data sold through secure marketplaces  

---

## ğŸ‘¥ Team  

- **Saif Chouaya** â€“ AI Student  
- **Olfa Boutiti** â€“ Biomedical Engineering Student  
- **Aya Koshlev** â€“ Big Data Student  

---

## ğŸ™ Acknowledgments  

Thanks to our mentors, sponsors, and supporting institutions who helped us shape this vision.  

---

## ğŸ“š References  

- World Today News (Oct 2024) â€“ Coverage of rising cancer cases in Tunisia  
- National Library of Medicine (NCBI Gene) â€“ Genomic data resources  
- Academic research on AI, digital twins, and blockchain in healthcare  

---
